Organon & Co. (NYSE:OGN) Reaches New 52-Week High - Should You Buy?

Key Points

• Organon shares reached a new 52-week high of $13.60, exceeding the average analyst price target of $11.40. Despite recent target increases from BNP Paribas Exane and Piper Sandler, analysts remain cautious, with an overall “Reduce” rating from MarketBeat.
• The company has a $3.57 billion market capitalization and trades at a P/E ratio of 17.66, while carrying a high debt-to-equity ratio of 8.43. Its shares have risen above the 200-day moving average of $10.56.
• Organon declared a quarterly dividend of $0.02 per share, equivalent to an annualized $0.08 dividend and a 0.6% yield. Institutional investors own 77.43% of the stock, with major holders including Vanguard, State Street, and AQR Capital Management.

Shares of Organon & Co. (NYSE:OGN - Get Free Report) hit a new 52-week high during mid-day trading on Friday . The company traded as high as $13.60 and last traded at $13.5950, with a volume of 2403529 shares trading hands. The stock had previously closed at $13.55.

Analyst Ratings Changes

Several analysts have issued reports on OGN shares. Weiss Ratings lowered Organon & Co. from a "hold (c)" rating to a "hold (c-)" rating in a report on Monday. Zacks Research raised Organon & Co. from a "strong sell" rating to a "hold" rating in a research report on Tuesday, April 14th. BNP Paribas Exane reiterated a "neutral" rating and set a $14.00 price objective (up from $12.00) on shares of Organon & Co. in a research note on Wednesday, April 29th. Finally, Piper Sandler raised shares of Organon & Co. from an "underweight" rating to a "neutral" rating and increased their target price for the stock from $5.00 to $14.00 in a report on Tuesday, April 28th. Five analysts have rated the stock with a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Reduce" and an average target price of $11.40.

Organon & Co. Stock Performance

The stock has a market cap of $3.57 billion, a P/E ratio of 17.66, a PEG ratio of 1.26 and a beta of 1.55. The company has a debt-to-equity ratio of 8.43, a current ratio of 1.95 and a quick ratio of 1.42. The firm's 50-day moving average price is $13.49 and its 200-day moving average price is $10.56.

Organon & Co. Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be issued a dividend of $0.02 per share. This represents a $0.08 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Organon & Co.'s dividend payout ratio is 10.39%.

Institutional Investors Weigh In On Organon & Co.

Large investors have recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in Organon & Co. by 2.7% in the 4th quarter. Vanguard Group Inc. now owns 36,916,382 shares of the company's stock worth $264,690,000 after acquiring an additional 987,979 shares during the last quarter. State Street Corp grew its holdings in shares of Organon & Co. by 2.8% in the fourth quarter. State Street Corp now owns 9,597,761 shares of the company's stock valued at $68,816,000 after purchasing an additional 262,185 shares in the last quarter. AQR Capital Management LLC grew its holdings in shares of Organon & Co. by 105.2% in the fourth quarter. AQR Capital Management LLC now owns 8,570,958 shares of the company's stock valued at $61,282,000 after purchasing an additional 4,394,814 shares in the last quarter. Private Management Group Inc. increased its position in Organon & Co. by 38.3% in the fourth quarter. Private Management Group Inc. now owns 4,347,073 shares of the company's stock worth $31,169,000 after purchasing an additional 1,204,979 shares during the last quarter. Finally, UBS Group AG increased its position in Organon & Co. by 55.2% in the fourth quarter. UBS Group AG now owns 4,295,002 shares of the company's stock worth $30,795,000 after purchasing an additional 1,527,492 shares during the last quarter. 77.43% of the stock is owned by institutional investors.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source